Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - X4 Pharmaceuticals, Inc | asns-ex322_27.htm |
| EX-31.2 - EX-31.2 - X4 Pharmaceuticals, Inc | asns-ex312_28.htm |
| EX-31.1 - EX-31.1 - X4 Pharmaceuticals, Inc | asns-ex311_29.htm |
| 10-Q - 10-Q - X4 Pharmaceuticals, Inc | asns-10q_20180331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Arsanis, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, René Russo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: May 10, 2018 |
|
By: |
/s/ René Russo |
|
|
|
|
René Russo |
|
|
|
|
President and Chief Executive Officer |
|
|
|
|
(principal executive officer) |